◆ 会议时间：2023年10月13日至15日
◆ 会议地点：中国 香港

◆ 会议简介：

2023年第15届亚澳介入治疗神经放射学联合会(AAFITN)两年一次大会将于2023年10月13日至15日在中国香港举行。

AAFITN 2023 - 15th Asian-Australasian Federation of Interventional and Therapeutic Neuroradiology (AAFITN) Biennial Congress

Date: October 13-15, 2023
Venue: Hong Kong, China

Asian-Australasian Federation of Interventional and Therapeutic Neuroradiology (AAFITN) was founded in 1994 by Professor Ling Feng. The last 5th Congress was held in Hong Kong with the late Prof. John Ching-Kwong Kwok (2002 - Hong Kong). The 15th AAFITN Biennial Congress will be in Hong Kong 13rd to 15th October, 2023, 21 years after the last. See you all in Hong Kong! George Wong

摘要征文投稿：

点此提交摘要>>>Submit Abstract>>>

Acceptance

1. Abstracts selected will be published online in October 2023 on the AAFITN2023 Web site.
2. If the abstract is submitted to more than one meeting, investigators must include new and scientifically meaningful information/results at time of submission to the AAFITN2023.
3. Abstracts accepted for presentation at AAFITN 2023 cannot be presented at another national or international meeting held prior to 15th October, 2023.
4. The manuscript covered by the abstract must not be published prior to the time of abstract submission. Abstracts associated with a manuscript published between the time of submission and time of presentation may still be presented at AAFITN2023 but will not be included in the AAFITN2023 Website or subsequent publication. Authors must contact us to be removed from the abstract publication prior to the event, once published online or in print. Please notify us by sending an e-mail to support@aafitn2023.org.
5. Abstract grading is blinded. Abstracts are selected on the basis of scientific merit and are allocated to oral or poster presentations.
6. Guidelines for presentations will be provided to authors of accepted abstracts.
7. Abstract acceptance/non-acceptance status will be e-mailed to the submitting author in early August to the e-mail address provided during the submission process.

1. Request “oral or poster” or “poster only” preferred presentation on the Presentation Preference tab of the Submitter Site. The selection of one of these options will neither prejudice acceptance nor guarantee an oral or poster presentation because abstracts must be arranged to fit into a thematic group for presentation.
2. All presentations and question-and-answer sessions will be conducted in English. Presenters may request assistance from the moderator who will repeat or rephrase questions from the audience or they may ask a colleague in the audience to help translate.
3. Submission of an abstract constitutes a commitment by the author(s) to present it if accepted. Failure to present, if not justified, will jeopardize future acceptance of abstracts.
4. The Organizing Committee of the AAFITN2023, reserves the right to all video or audio recordings of presentations at the AAFITN2023.
5. The presenter is responsible for all expenses associated with the submission and presentation of an abstract (e.g. registration, airfare, lodging, etc.)
6. All poster presentations must be in electronic format. Electronic presentations must be submitted by 15th September 2023. Instructions for submission will be sent to the presenting author via e-mail in early August 2023.
7. If you are referencing work previously published by another author, please be sure to include a complete citation at the bottom of the appropriate slide.
8. Recording Policy:
   • Unauthorized recording of the AAFITN2023 Sessions or Conference is prohibited, whether by video, still or digital photography, audio or any other recording or reproduction mechanism. This includes recording of presentations and supporting audiovisual materials and of poster presentations and supporting poster materials.
   • The Organizing Committee of the AAFITN2023 reserve the rights to all recordings or reproductions of presentations at AAFITN2023 Sessions or Conference.

1. If an author's name appears on more than one abstract, it must be identical on each abstract.
2. The submitting author is designated as the presenting author. You may rearrange the order of the authors; however, the senior author must always be listed last. The presenter must be an author of the abstract.
3. Additions or deletions of author names will not be permitted after 15th July, 2023, 11:59 pm CDT.

1. The AAFITN2023 is a forum for the presentation of novel research findings. The submitted abstract or manuscript covered by the abstract must not be published prior to the time of abstract submission. Abstracts associated with a manuscript published between the time of submission and time of presentation may still be presented at AAFITN2023 but will not be included in the AAFITN2023 Website or subsequent publication. Authors must contact us to be removed from the abstract publication prior to the event, once published online or in print. Please notify us by sending an e-mail to support@aafitn2023.org.
2. Abstract data may not be presented at any national or international meeting held prior to the date and time of presentation.
3. Written embargoed information cannot be shared with anyone, but one-on-one embargoed media interviews can be conducted as long as the reporter agrees to abide by the embargo policy. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation.
4. Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.
5. Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals will be disqualified.
6. Because of submitted abstracts, resubmission of an abstract to make revisions is not permitted after 15th July, 2023, 11:59 pm CDT.
7. To ensure that the abstract receives proper scientific consideration, please make sure that the abstract is submitted to the appropriate category. A list of the abstract categories and their definitions is available on the submission site.
8. Proofread abstracts carefully to avoid errors before submission. No proof pages will be sent to authors. Revisions to abstracts will not be permitted after the 15th July, 2023, 11:59 pm CDT submission deadline.

1. Requests for withdrawal of an abstract must be received in writing by 15th July, 2023.

1. An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.

1. Describe briefly the objectives of the study unless they are contained in the title. Include a brief statement of methods. State findings in detail sufficient to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.
2. Abstracts may have the following identifiable sections, but they are not mandatory: Introduction, Hypothesis, Methods, Results, and Conclusions. You may include a hypothesis, but only if it is appropriate to do so.
3. The abstract must contain a brief section on Methods/Methodology.
4. Use generic drug names.
5. Do not begin sentences with numerals.
6. Standard abbreviations may be used without definition. Non-standard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
7. Do not include author or institution names, references, credits or grant support in the abstract.
8. Do not include the names or personal information of any patient participating in the study or trial.
9. Abstracts are limited to 1,950 characters (about 380 words.) This includes text and any graphic. Addition of a graphic deducts 250 characters.
10. Tables must be submitted as graphics. Do not submit a table or figure in Word as it may not format correctly in the web site or subsequent publication.
11. Do not add paragraph breaks within the body of the abstract.

1. After the 15th July, 2023, 11:59 pm CDT deadline, abstracts may not be revised in any way.
2. Additions or deletions of author names will not be permitted after 15th July, 2023, 11:59 pm CDT.
3. Proofread abstracts carefully to avoid errors before submission.

1. Acute Ischemic Stroke
2. Cerebral Aneurysm
3. Cerebral Arteriovenous Malformation
4. Dural Arteriovenous Fistulae
5. Other head and neck pathologies
6. Other neurovascular diseases

注册费：

Registration Fees
Registration is available only through Online Registration System. The payment of registration fee is processed in United States Dollar (USD) or Hong Kong Dollar (HKD) for online payment via PayPal and in Hong Kong Dollar (HKD) for payment via cheque or FPS.

1. Admission to all congress scientific sessions
2. Admission to exhibition and poster area
3. Congress materials
4. Coffee breaks and Luncheons (13 Oct and 14 Oct)
5. E-certificate of Attendance

◆ 参会对象：心脏病学家、放射科医生、儿科医生、工程师、基础科学家和影像技术专家，医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。